MOH Molina Healthcare (MOH) Insider Trading, Ownership & Congress Trades
Insurance · Hospital & medical service plans · CIK 0001179929
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
363
13F, latest reported quarter
What the filings say about MOH
Insiders, 180 days
-$3.4M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2025-11-12
Molina Healthcare insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MOLINA HEALTHCARE, INC. insiders sold a net $3.4M of stock across 169 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 15, 2024.
- The trade is 4.7% of the 12,815 shares held after it.
- 1 other insider sold within 30 days.
- 363 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer HEBERT MAURICE sold about $114.9K of MOH on May 14, 2026; 1 other insider sold within 30 days and 363 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jul 29, 2024.
- The trade is 26.5% of the 67,175 shares held after it.
- 1 other insider sold within 30 days.
- 363 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Barlow Jeff D. sold about $3.3M of MOH on May 11, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 363 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Aug 6, 2025.
- The trade is 2.9% of the 17,227 shares held after it.
- No other insider sold within 30 days.
- 363 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ROMNEY RONNA sold about $74.3K of MOH on Mar 12, 2026; 363 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 9.1% of the 8,747 shares held after it.
- No other insider bought within 30 days.
- 363 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ZORETIC RICHARD C bought about $100.1K of MOH on Feb 11, 2026; 363 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Apr 29, 2025.
- The trade is 3.1% of the 11,352 shares held after it.
- No other insider sold within 30 days.
- 363 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schapiro Richard M sold about $51.1K of MOH on Nov 24, 2025; 363 funds added in the latest 13F quarter.169 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$3.4M over 180 days
below 54% of Insurance
Congress
no House purchase disclosed in the last 12 months
Funds
363 funds bought in last quarter
more than 79% of Insurance
Revenue
+11.7% year over year
more than 57% of Insurance
Margin
1.0% net margin
below 81% of Insurance
Buybacks
$1.0B repurchased, FY to 2025-12-31
more than 86% of Insurance
Short interest
6.2% of the float short (float per yahoo 2026-10-27) · 3.7 days to cover · settled 2026-10-15
more than 85% of Insurance
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch MOH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+27.2%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MOH: institutional holders (13F)
13F holdings, latest reported quarter
6,572,156 sh
$1.5B
3,560,601 sh
$806.9M
2,790,243 sh
$638.1M
2,562,913 sh
$586.1M
2,511,490 sh
$574.4M
Congress trades in MOH
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-11-12 · disclosed 33 days later
$1,001 - $15,000
Sold 2025-09-04 · disclosed 33 days later
$1,001 - $15,000
Bought 2025-08-05 · disclosed 38 days later
$1,001 - $15,000
Sold 2025-05-30 · disclosed 7 days later
$1,001 - $15,000
Bought 2025-05-15 · disclosed 25 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MOH planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
MOH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P SmallCap Health Care ETF
$6.3M position · as of 2026-05-31
4.8%
Sovereign's Capital Flourish Fund
$3.7M position · as of 2026-07-31
4.2%
Invesco S&P SmallCap 600 Revenue ETF
$59.8M position · as of 2026-05-31
3.2%
DIAMOND HILL SELECT FUND
$17.4M position · as of 2026-06-30
3.2%
Easterly Snow Small Cap Value Fund
$1.5M position · as of 2026-05-31
3.2%
Towle Value ETF
$5.6M position · as of 2026-05-29
2.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Molina Healthcare, Inc. Pac
Cycle 2026 · $1,449K spent
$1.4M
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Joseph Zubretsky
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$18.3M
-$15.3M
$5.1M
-18%
+62%
2024
$21.9M
$15.4M
$5.4M
+37%
+50%
2023
$21.5M
$25.2M
$4.7M
+70%
+43%
2022
$22.1M
$41.7M
$5.4M
+55%
+40%
2021
$20.0M
$75.9M
$4.2M
+50%
+29%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $3.4M sold by insiders over 180 days, 363 funds added last quarter. Each figure is a federal filing, dated the day it went public.
MOH financials
Revenue growth
+11.7%
XBRL, annual
Net margin
1.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$44.1B
four quarters, 2025-10-01 to 2026-09-30
Revenue, TTM MOH
| FY Dec 2025 | $45.4B |
| FY Dec 2024 | $40.6B |
| FY Dec 2023 | $34.1B |
| FY Dec 2022 | $32.0B |
| FY Dec 2021 | $27.8B |
| Sep 2026 | $11.1B |
| Jun 2026 | $10.9B |
| Mar 2026 | $10.8B |
| Dec 2025 | $11.4B |
| Sep 2025 | $11.5B |
| Jun 2025 | $11.4B |
| Mar 2025 | $11.1B |
| Dec 2024 | $10.5B |
At each fiscal year end
Single quarter
Net margin, TTM
-0.1%
net income over revenue, 2025-10-01 to 2026-09-30
Net margin, TTM MOH
| FY Dec 2025 | +1.0% |
| FY Dec 2024 | +2.9% |
| FY Dec 2023 | +3.2% |
| FY Dec 2022 | +2.5% |
| FY Dec 2021 | +2.4% |
| Sep 2026 | +0.3% |
| Jun 2026 | +0.6% |
| Mar 2026 | +0.1% |
| Dec 2025 | -1.4% |
| Sep 2025 | +0.7% |
| Jun 2025 | +2.2% |
| Mar 2025 | +2.7% |
| Dec 2024 | +2.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$238.0M
operating cash flow minus capex, 2025-10-01 to 2026-09-30
Free cash flow, TTM MOH
| FY Dec 2025 | -$636.0M |
| FY Dec 2024 | $544.0M |
| FY Dec 2023 | $1.6B |
| FY Dec 2022 | $682.0M |
| FY Dec 2021 | $2.0B |
| Sep 2026 | -$196.0M |
| Jun 2026 | -$324.0M |
| Mar 2026 | $1.1B |
| Dec 2025 | -$297.0M |
| Sep 2025 | -$163.0M |
| Jun 2025 | -$344.0M |
| Mar 2025 | $168.0M |
| Dec 2024 | -$235.0M |
At each fiscal year end
Single quarter
Debt to equity
0.91x
long-term 2026-09-30 plus current 2020-12-31 (69 months older than the period end); equity 2026-09-30
Debt to equity MOH
| FY Dec 2025 | 0.93x |
| FY Dec 2024 | 0.65x |
| FY Dec 2023 | 0.52x |
| FY Dec 2022 | 0.73x |
| FY Dec 2021 | 0.83x |
| Sep 2026 | 0.91x |
| Jun 2026 | 0.90x |
| Mar 2026 | 0.92x |
| Dec 2025 | 0.93x |
| Sep 2025 | 0.87x |
| Jun 2025 | 0.73x |
| Mar 2025 | 0.83x |
| Dec 2024 | 0.65x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.09x
TTM operating cash flow over long-term 2026-09-30 plus current 2020-12-31 (69 months older than the period end)
Cash flow to debt MOH
| FY Dec 2025 | -0.14x |
| FY Dec 2024 | 0.22x |
| FY Dec 2023 | 0.76x |
| FY Dec 2022 | 0.36x |
| FY Dec 2021 | 0.98x |
| Sep 2026 | 0.09x |
| Jun 2026 | 0.10x |
| Mar 2026 | 0.09x |
| Dec 2025 | -0.14x |
| Sep 2025 | -0.13x |
| Jun 2025 | 0.16x |
| Mar 2025 | 0.17x |
| Dec 2024 | 0.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-1.2%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on equity MOH
| FY Dec 2025 | +11.0% |
| FY Dec 2024 | +27.1% |
| FY Dec 2023 | +30.4% |
| FY Dec 2022 | +28.3% |
| FY Dec 2021 | +27.9% |
| Sep 2026 | -1.2% |
| Jun 2026 | -0.2% |
| Mar 2026 | +4.5% |
| Dec 2025 | +11.0% |
| Sep 2025 | +19.7% |
| Jun 2025 | +23.9% |
| Mar 2025 | +26.7% |
| Dec 2024 | +27.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-0.3%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on assets MOH
| FY Dec 2025 | +3.0% |
| FY Dec 2024 | +7.7% |
| FY Dec 2023 | +8.0% |
| FY Dec 2022 | +6.5% |
| FY Dec 2021 | +6.1% |
| Sep 2026 | -0.3% |
| Jun 2026 | -0.0% |
| Mar 2026 | +1.1% |
| Dec 2025 | +3.0% |
| Sep 2025 | +5.6% |
| Jun 2025 | +7.2% |
| Mar 2025 | +7.4% |
| Dec 2024 | +7.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital MOH
| FY Dec 2025 | +17.4% |
| FY Dec 2024 | +50.2% |
| FY Dec 2023 | +87.3% |
| FY Dec 2022 | +116.4% |
| FY Dec 2021 | +320.1% |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | +12.4% |
| Dec 2025 | +17.4% |
| Sep 2025 | +27.7% |
| Jun 2025 | +33.9% |
| Mar 2025 | +38.8% |
| Dec 2024 | +50.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+2.1%
operating income (EBIT proxy) over average of 2025-09-30 and 2026-09-30 minus current liabilities
Return on capital employed MOH
| FY Dec 2025 | +9.8% |
| FY Dec 2024 | +23.6% |
| FY Dec 2023 | +25.8% |
| FY Dec 2022 | +22.1% |
| FY Dec 2021 | +21.0% |
| Sep 2026 | +2.1% |
| Jun 2026 | +2.4% |
| Mar 2026 | +5.2% |
| Dec 2025 | +9.8% |
| Sep 2025 | +16.9% |
| Jun 2025 | +21.1% |
| Mar 2025 | +22.5% |
| Dec 2024 | +23.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MOH
| FY Dec 2025 | 19.63x |
| FY Dec 2024 | 14.24x |
| FY Dec 2023 | 19.25x |
| FY Dec 2022 | 24.35x |
| FY Dec 2021 | 28.27x |
| Sep 2026 | n/a |
| Jun 2026 | 2,287.00x |
| Mar 2026 | 36.42x |
| Dec 2025 | 19.63x |
| Sep 2025 | 11.84x |
| Jun 2025 | 14.67x |
| Mar 2025 | 15.90x |
| Dec 2024 | 14.24x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.0B
market value at close 2026-10-26 on 2026-10-16 shares, plus long-term 2026-09-30 plus current 2020-12-31 (69 months older than the period end), minus cash 2026-09-30
Enterprise value MOH
| FY Dec 2025 | $8.4B |
| FY Dec 2024 | $14.9B |
| FY Dec 2023 | $18.4B |
| FY Dec 2022 | $17.5B |
| FY Dec 2021 | $16.3B |
| Sep 2026 | $9.2B |
| Jun 2026 | $10.7B |
| Mar 2026 | $5.3B |
| Dec 2025 | $8.4B |
| Sep 2025 | $9.8B |
| Jun 2025 | $15.0B |
| Mar 2025 | $17.0B |
| Dec 2024 | $14.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield MOH
| FY Dec 2025 | -7.1% |
| FY Dec 2024 | +3.3% |
| FY Dec 2023 | +7.5% |
| FY Dec 2022 | +3.5% |
| FY Dec 2021 | +11.0% |
| Sep 2026 | +2.4% |
| Jun 2026 | +2.3% |
| Mar 2026 | +3.7% |
| Dec 2025 | -7.1% |
| Sep 2025 | -5.5% |
| Jun 2025 | +2.6% |
| Mar 2025 | +2.9% |
| Dec 2024 | +3.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MOH
| FY Dec 2025 | n/a |
| FY Dec 2024 | 1.60x |
| FY Dec 2023 | 0.50x |
| FY Dec 2022 | 1.19x |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 1.30x |
| Mar 2025 | 1.27x |
| Dec 2024 | 1.60x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $45.4B | $40.6B | $34.1B | $32.0B |
| Operating income | $781.0M | $1.7B | $1.6B | $1.2B |
| Net income | $472.0M | $1.2B | $1.1B | $792.0M |
| EPS (diluted) | 8.92 | 20.42 | 18.77 | 13.55 |
| Operating cash flow | -$535.0M | $644.0M | $1.7B | $773.0M |
| Cash | $4.2B | $4.7B | $4.8B | $4.0B |
| Long-term debt | $3.8B | $2.9B | $2.2B | $2.2B |
| Buybacks | $1.0B | $1.0B | $0 | $400.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
MOH Stock Sonar score 6/7 axes
Find similar shapesCompareMOH ranks highest on growth (57th percentile) and institutional and government (54th), and lowest on financial health (15th), among Insurance peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MOH filings, in plain words
Are Molina Healthcare insiders buying or selling MOH?
In the 180 days to 2026-10-28, Molina Healthcare insiders were net sellers, a net $3.4M across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded MOH?
Yes. In the year to 2026-10-28, 0 House members disclosed buying MOH and 1 House member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2025-11-12.
Read the full summary
In the 180 days to 2026-10-28, Molina Healthcare insiders were net sellers of MOH, a net $3.4M across purchases and sales reported on Form 4 by 2 sellers. In the year to 2026-10-28, 0 members of Congress disclosed buying MOH and 1 member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2025-11-12. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
